Nicole Bodmer
YOU?
Author Swipe
View article: Results in pediatric T‐ALL patients treated in trial AIEOP‐BFM ALL 2009: Prognostic factors in the context of modern risk‐adapted therapy
Results in pediatric T‐ALL patients treated in trial AIEOP‐BFM ALL 2009: Prognostic factors in the context of modern risk‐adapted therapy Open
To improve the outcome of pediatric T‐cell acute lymphoblastic leukemia (T‐ALL) patients, the AIEOP‐BFM ALL 2009 trial modified T‐ALL stratification and treatment based on AIEOP‐BFM ALL 2000 and other pediatric ALL groups' results. This re…
View article: Trends in pivotal clinical trial design and biomarker use: a retrospective analysis of oncology drug approval in Switzerland from 2001 to 2020
Trends in pivotal clinical trial design and biomarker use: a retrospective analysis of oncology drug approval in Switzerland from 2001 to 2020 Open
Introduction Cancer treatment has advanced rapidly in recent decades. Regulatory approval of cancer therapies relies on pivotal clinical trials, with phase III, randomised controlled trials (RCTs) regarded as the gold standard. However, th…
View article: Approaches to Invasive Fungal Diseases in Paediatric Cancer Centres: An Analysis of Current Practices and Challenges in Germany, Austria and Switzerland
Approaches to Invasive Fungal Diseases in Paediatric Cancer Centres: An Analysis of Current Practices and Challenges in Germany, Austria and Switzerland Open
Background Invasive fungal diseases (IFD) pose significant challenges in paediatric oncology. Their management is complicated by limited paediatric‐specific evidence, lack of standardised protocols and variability in resources across centr…
View article: Update on long-term outcomes of a cohort of patients with TCF3::HLF positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation
Update on long-term outcomes of a cohort of patients with TCF3::HLF positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation Open
Not available.
View article: <i>ATM</i> germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies
<i>ATM</i> germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies Open
Ataxia-telangiectasia (A-T) is an autosomal-recessive disorder caused by pathogenic variants (PVs) of the ATM gene, predisposing children to hematological malignancies. We investigated their characteristics and outcomes to generate data-ba…
View article: Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Open
Introduction Treatment of relapsed/refractory acute lymphoblastic leukemia (r/r ALL) remains challenging in spite of recent progress with immunotherapy and targeted small-molecule combinations. Growing awareness of the molecular complexity…
View article: Pediatric-Inspired Regimens in the Treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults: A Systematic Review
Pediatric-Inspired Regimens in the Treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults: A Systematic Review Open
Adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) have significantly worse outcomes than their younger counterparts. Current treatment guidelines rely mostly on non-randomized retrospective studies. We performed a …
View article: Outcome prediction in pediatric fever in neutropenia: Development of clinical decision rules and external validation of published rules based on data from the prospective multicenter SPOG 2015 FN definition study
Outcome prediction in pediatric fever in neutropenia: Development of clinical decision rules and external validation of published rules based on data from the prospective multicenter SPOG 2015 FN definition study Open
Background Fever in neutropenia (FN) remains a serious complication of childhood cancer therapy. Clinical decision rules (CDRs) are recommended to help distinguish between children at high and low risk of severe infection. The aim of this …
View article: S111: TREATMENT OF POST-TRANSPLANT RELAPSE IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH BCP ALL USING CD19-CAR-T: A EUROPEAN RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA
S111: TREATMENT OF POST-TRANSPLANT RELAPSE IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH BCP ALL USING CD19-CAR-T: A EUROPEAN RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA Open
Background: Relapse after allogeneic hematopoietic stem cell transplantation (SCT) for very high-risk acute lymphoblastic leukemia (ALL) has a dismal prognosis. The potentially curative effect of a second SCT is jeopardized by a high rate …
View article: Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials
Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials Open
Outcome improvement for T-cell acute lymphoblastic leukemia and Induction failure in a contemporary treatment era.
View article: Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction
Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction Open
Asparaginase (ASNase) has become one of the key components in the treatment of acute lymphoblastic leukemia (ALL) by exploiting the inability of leukemic cells to synthesize the otherwise nonessential amino acid asparagine.1,2 Currently, 3…
View article: Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemia
Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemia Open
Although initial central nervous system (CNS) involvement is rarely detected in childhood acute lymphoblastic leukemia (ALL), risk-adapted CNS-directed therapy is essential for all patients. Treatment intensity depends on the initial CNS s…
View article: Invasive Fungal Diseases Impact On Outcome of Childhood ALL – An Analysis of the International Trial AIEOP-BFM ALL 2009
Invasive Fungal Diseases Impact On Outcome of Childhood ALL – An Analysis of the International Trial AIEOP-BFM ALL 2009 Open
In children with acute lymphoblastic leukemia (ALL), risk groups for invasive fungal disease (IFD) with need for antifungal prophylaxis are not well characterized, and with the advent of new antifungal compounds, current data on outcome ar…
View article: Predicting fever in neutropenia with safety‐relevant events in children undergoing chemotherapy for cancer: The prospective multicenter SPOG 2015 FN Definition Study
Predicting fever in neutropenia with safety‐relevant events in children undergoing chemotherapy for cancer: The prospective multicenter SPOG 2015 FN Definition Study Open
Background Fever in neutropenia (FN) remains a frequent complication in pediatric patients undergoing chemotherapy for cancer. Preventive strategies, like primary antibiotic prophylaxis, need to be evidence‐based. Procedure Data on pediatr…
View article: Time to Antibiotics in Pediatric Patients with Fever in Neutropenia during Chemotherapy for Cancer -- Data from the Prospective Multicenter SPOG 2015 FN Definition Study
Time to Antibiotics in Pediatric Patients with Fever in Neutropenia during Chemotherapy for Cancer -- Data from the Prospective Multicenter SPOG 2015 FN Definition Study Open
Background. Fever in neutropenia (FN) remains an unavoidable, potentially lethal complication of chemotherapy. Timely administration of empirical broad-spectrum intravenous antibiotics has become standard of care. But the impact of time to…
View article: Predicting Fever in Neutropenia with Safety Relevant Events in Children Undergoing Chemotherapy for Cancer: the Prospective Multicenter SPOG 2015 FN Definition Study
Predicting Fever in Neutropenia with Safety Relevant Events in Children Undergoing Chemotherapy for Cancer: the Prospective Multicenter SPOG 2015 FN Definition Study Open
Background Fever in neutropenia (FN) remains a frequent complication in pediatric patients undergoing chemotherapy for cancer. There are only conflicting and weak recommendations for and against antibiotic prophylaxis during chemotherapy. …
View article: Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series
Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series Open
Summary No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (m…
View article: CAR-T cell therapy in less than 2 year old children with infant acute lymphoblastic leukemia : case reports and review of the literature
CAR-T cell therapy in less than 2 year old children with infant acute lymphoblastic leukemia : case reports and review of the literature Open
Infant acute lymphoblastic leukemia (infant ALL) is known for its poor prognosis. Current treatment protocols include aggressive chemotherapy and allogeneic stem cell transplantation but prognosis remains poor. Immunotherapy is a new appro…
View article: Lineage-restricted sympathoadrenal progenitors confer neuroblastoma origin and its tumorigenicity
Lineage-restricted sympathoadrenal progenitors confer neuroblastoma origin and its tumorigenicity Open
Neuroblastoma (NB) is the most common cancer in infants and it accounts for six percent of all pediatric malignancies. There are several hypotheses proposed on the origins of NB. While there is little genetic evidence to support this, the …
View article: Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols Open
ABL-class fusions other than BCR-ABL1 characterize around 2-3% of precursor B-cell acute lymphoblastic leukemia. Case series indicated that patients suffering from these subtypes have a dismal outcome and may benefit from the introduction …
View article: Durable remissions in <i>TCF3-HLF</i> positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation
Durable remissions in <i>TCF3-HLF</i> positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation Open
Persisting clones in compartments other than bone marrow may not be covered by MRD quantification but could still be responsive to blinatumomab therapy.The responses detected in this TCF3-HLF-positive ALL cohort are encouraging and suggest…
View article: Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL Open
.